Slingshot members are tracking this event:

Phase 1/2 initial data of Genmab's (GMAB) Enapotamab vedotin in Solid tumors to be presented at IASLC 2019 WCLC September 8, 2019

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks
GMAB Community voting in process
SGEN Community voting in process
Slingshot Insights Explained
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Enapotamab Vedotin, Solid Tumors, Iaslc